Upstream / Downstream

pathwayImage

Explore pathways related to this product.

Dec 31st Santa Cruz will discontinue a
large number of polyclonal products as
a result of the USDA settlement that was
made public May 19th.

Find CST Equivalent

Questions?

Find answers on our FAQs page.

ANSWERS  

PhosphoSitePlus® Resource

  • Additional protein information
  • Analytical tools

LEARN MORE

We recommend the following alternatives

W   IHC       H
REACTIVITY SENSITIVITY MW (kDa) Isotype
140 Rabbit 

Product Usage Information

Storage: Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

Specificity / Sensitivity

TrkA (14G6) Rabbit mAb detects endogenous levels of total TrkA protein. This antibody does not cross-react with TrkB.


Source / Purification

Monoclonal antibody is produced by immunizing animals with a synthetic peptide surrounding Arg220 of human TrkA.

The family of Trk receptor tyrosine kinases consists of TrkA, TrkB, and TrkC. While the sequence of these family members is highly conserved, they are activated by different neurotrophins: TrkA by NGF, TrkB by BDNF or NT4, and TrkC by NT3 (1). Neurotrophin signaling through these receptors regulates a number of physiological processes, such as cell survival, proliferation, neural development, and axon and dendrite growth and patterning (1). In the adult nervous system, the Trk receptors regulate synaptic strength and plasticity. TrkA regulates proliferation and is important for development and maturation of the nervous system (2). Phosphorylation at Tyr490 is required for Shc association and activation of the Ras-MAP kinase cascade (3,4). Residues Tyr674/675 lie within the catalytic domain, and phosphorylation at these sites reflects TrkA kinase activity (3-6). Point mutations, deletions, and chromosomal rearrangements (chimeras) cause ligand-independent receptor dimerization and activation of TrkA (7-10). TrkA is activated in many malignancies including breast, ovarian, prostate, and thyroid carcinomas (8-13). Research studies suggest that expression of TrkA in neuroblastomas may be a good prognostic marker as TrkA signals growth arrest and differentiation of cells originating from the neural crest (10).


1.  Huang, E.J. and Reichardt, L.F. (2003) Annu Rev Biochem 72, 609-42.

2.  Segal, R.A. and Greenberg, M.E. (1996) Annu Rev Neurosci 19, 463-89.

3.  Stephens, R.M. et al. (1994) Neuron 12, 691-705.

4.  Marsh, H.N. et al. (2003) J Cell Biol 163, 999-1010.

5.  Obermeier, A. et al. (1993) EMBO J 12, 933-41.

6.  Obermeier, A. et al. (1994) EMBO J 13, 1585-90.

7.  Arevalo, J.C. et al. (2001) Oncogene 20, 1229-34.

8.  Reuther, G.W. et al. (2000) Mol Cell Biol 20, 8655-66.

9.  Greco, A. et al. (1997) Genes Chromosomes Cancer 19, 112-23.

10.  Pierotti, M.A. and Greco, A. (2006) Cancer Lett 232, 90-8.

11.  Lagadec, C. et al. (2009) Oncogene 28, 1960-70.

12.  Greco, A. et al. (2010) Mol Cell Endocrinol 321, 44-9.

13.  Ødegaard, E. et al. (2007) Hum Pathol 38, 140-6.


Entrez-Gene Id 4914
Swiss-Prot Acc. P04629


For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
U.S. Patent No. 5,675,063.

2508
TrkA (14G6) Rabbit mAb